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Abstract
Background: More than 90 immunologically distinct serotypes of Streptococcus pneumoniae exist, and it is not fully
elucidated whether the serotype is a risk factor for severity of invasive pneumococcal disease (IPD). Our hypothesis
is that serotypes differ in their capacity to cause septic shock.
Methods: We performed a retrospective study in Southern Sweden based upon 513 patients with IPD in the pre-
vaccine era 2006–2008. The serotype, co-morbidity, and sepsis severity were determined. Serotypes were compared to
serotype 14 as a reference and grouped according to their invasive potential, that is, high (serogroups 1, 5 and 7),
intermediate (serogroups 4, 9, 14 and 18) and, finally, low invasive potential (serogroups 3, 6, 8, 15, 19, 23 and 33).
Results: Patients with S. pneumoniae serotype 3 had significantly more often septic shock (25%, odds ratio (OR) 6.33
[95% confidence interval (CI) 1.59-25.29]), higher mortality (30%, OR 2.86 [CI 1.02-8.00]), and more often co-morbidities
(83%, OR 3.82 [CI 1.39-10.54]) when compared to serotype 14. A significant difference in age and co-morbidities
(p≤0.001) was found when patient data were pooled according to the invasive potential of the infecting pneumococci.
The median age and percentage of patients with underlying co-morbidities were 72 years and 79%, respectively, for
serogroups associated with low invasiveness, 68 years and 61%, respectively, for serogroups with intermediate
invasiveness, and, finally, 62 years and 48%, respectively, for serogroups with high invasiveness. No difference in sepsis
severity was found between the three groups.
Conclusions: S. pneumoniae serotype 3 more often caused septic shock compared to serotype 14. Our results support
the hypothesis that serotypes with high invasiveness mainly cause IPD in younger patients with less co-morbidities.
In contrast, serogroups with low and intermediate invasive potential mostly cause IPD in the elderly with defined
co-morbidities, and thus can be considered as opportunistic.
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Background
Streptococcus pneumoniae is a common colonizer of the
human respiratory tract and is associated with morbidity
and mortality worldwide. The species is the leading bac-
terial cause of acute otitis media, sinusitis, pneumonia and
a major cause of invasive infection, such as meningitis and
sepsis, i.e., invasive pneumococcal disease (IPD) [1].
S. pneumoniae is equipped with several virulence fac-
tors of which the composition of the polysaccharide
capsule, i.e., the serotype, is considered to be the most
important one [2]. Many serogroups are divided into se-
rotypes and to date more than 90 serotypes have been
defined. Variation in nasopharyngeal carriage rate, inva-
sive capacity and disease rate are related to specific sero-
types and serogroups. The invasive disease potential of a
particular serotype is related to the tendency to cause
IPD while colonizing the nasopharynx [3]. A significant
inverse correlation between invasive disease and carriage
rate has been observed [3]. In addition, other studies
have shown that S. pneumoniae with a low invasive po-
tential is more likely to infect the older population and
results in IPD with a more severe outcome [4,5].
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An important issue is whether the serotype is a risk
factor for IPD severity. Some studies suggest that host
factors such as underlying disease and age are more im-
portant determinants than a particular serotype [6,7]. In
contrast, certain serotypes are associated with more se-
vere outcome and mortality even after adjustment for
relevant host factors [4,8-10]. A meta-analysis by
Weinberger et al. in 2010 supports that the serotype
plays an important role in determining the outcome of
bacteremic pneumonia [11]. These authors also found
that particularly serotypes 3 and 19F, which have a
thicker capsule in vitro as measured with digital fluores-
cence microscopy, more frequently are associated with a
fatal outcome. Serotype 3 is independtly associated with
a higher incidence of septic shock as revealed in a study
by Garcia-Vidal et al. [12]. In parallel, experimental ani-
mal studies revealed that serotypes with a thicker cap-
sule are more virulent [13].
Clinical studies on sepsis severity in patients with IPD
that are correlated to the pneumococcal serotype are
scarce. To reveal whether or not serotypes differ in viru-
lence, we therefore chose septic shock as the primary
endpoint. A putative relationship between serotype and
the frequency of septic shock was studied in a defined
population in Southern Sweden (years 2006–2008). In
addition, mortality, age and co-morbidities were care-
fully documented. The prevalence of penicillin non-
susceptible pneumococci (PNSP) is only 3.0% among
nasopharyngeal carriage disease strains in the study area,
and a conjugated pneumococcal vaccine (PCV) not in-
cluded in the national vaccine program until 2009.
These two confounding factors could thus be excluded
in our analyses. Interestingly, we found that the fre-
quency of septic shock differed between serogroups and
that serotype 3 significantly more often caused septic
shock as compared to serotype 14.
Methods
Identification of patients
All cases with IPD in Sweden are reported to the
Swedish Institute for Communicable Disease Control.
The county of Skåne in southern Sweden including 1.2
million inhabitants was the study area. The pneumococ-
cal vaccine coverage was low in this community, and in
2007 1,366 doses of the 23-valent polysaccharide vaccine
and 1,287 doses of the 7-valent conjugated vaccine
(PCV7) were administered according to sales statistics
(data on file).
In this retrospective epidemiological study, 628 pa-
tients with IPD were identified during the years 2006–
2008. One hundred thirteen cases (58 men and 55
women, median age 65-years) were excluded since iso-
lates had been lost, and two cases were not included due
to absence of full medical records. The 28-day crude
mortality rate for the excluded patients was 13%.
Culture conditions and serotyping
Cultures, identification, PCR and antimicrobial suscepti-
bility tests were performed according to national guide-
lines [14,15]. Serotyping was done either with a capsular
reaction test or a gel diffusion method with antisera from
Statens Serum Institute (SSI; Copenhagen, Denmark)
[16,17]. Further serotyping was performed using the
Quellung reaction with antisera (SSI) [18] for the
serogroups 6, 7, 9, 18, 19, and 23 included in the conjugate
vaccines. In total, 4 isolates were missing, 10 isolates
belonging to a vaccine serogroup were not successfully
serotyped since the isolates were dead after thawing.
Patient and disease characteristics
The following data were collected from medical records;
age, gender, infection foci, admission to Intensive Care
Unit (ICU), septic shock, co-morbidities, immunosup-
pressive treatment, ongoing alcohol abuse or smoking,
and, finally, mortality after 28 days and after one year.
Co-morbidities were noted when a diagnosis was speci-
fied in the medical records and included diagnoses were
divided into the categories cardiovascular, lung, neuro-
logical, hematologic and autoimmune disease, liver and
renal failure, diabetes mellitus, solid cancer, splenec-
tomy, and HIV. Diagnoses in medical records after in-
patients hospital treatment in the county of Skåne have
proven to represent a high validity [19].
Severe sepsis and septic shock during the hospita-
lization were defined according to criteria in the surviv-
ing sepsis campaign [20]. Only objective parameters
were included in the analysis and absence of parameters
was thoroughly recorded. The sepsis severity grading in
relation to serotype was blinded for the examiner. Each
case was individually reviewed and data on previous
organ function was carefully searched for in the medical
records. The sepsis criteria were only considered fulfilled
if there was no other explanation for the change in
organ function other than sepsis. Oxygen saturation
obtained by pulse oximetry was converted to PaO2
according to a reference guide when required [21].
Septic shock was defined as severe sepsis with persisting
hypotension despite adequate fluid resuscitation with at
least 500 ml intravenous fluid given in 30 minutes. A pa-
tient that fulfilled the criteria for septic shock was
recorded even if the SIRS criterion was not fulfilled.
Statistical analyses
All data were analysed with SPSS, version 20. Potential
association between serotype and age, mortality, ICU
care, and frequency of septic shock was determined in
two different ways;
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Table 1 Characteristics of patients with IPD by infecting serotype and statistical comparison in relation to infection with serotype 14
Septic shock 28 day mortality Admitted to the ICU Any co-morbidity Two or more co-morbidities per patient Median age
Serotype (no) Percent of allisolates
No
(%) OR (CI) No (%) OR (CI)
No





Reference 11.7 3 (5) 1 8 (13) 1 8 (13) 1 35 (58) 1 10 (17) 1 70 (20–94) -----
1 (n=14) 2.7 0 (0) ----- 0 (0) ----- 0 (0) ----- 4 (29) 0.31 (0.09-1.07) 0 (0) ----- 49 (32–68) <0.001












(62) 3.57 (1.38–9.22) 75 (40–94) 0.530








30 (55) 0.92 (0.44–1.92) 15 (27) 1.86 (0.76–4.62) 66 (20–91) 0.550
6A (n=20) 3.9 0 (0) ----- 3 (15) 1.15
(0.27–4.82)
0 (0) ----- 14 (70) 1.78 (0.60–5.28)
11
(55) 6.11 (2.01–18.58) 73 (34–91) 0.669








18 (75) 2.29 (0.80–6.59) 9 (37) 3.00 (1.03–8.74) 73 (34–97) 0.760








33 (51) 0.74 (0.37–1.50) 16 (25) 1.63 (0.68–3.95) 63 (19–95) <0.001








11 (61) 1.20 (0.41–3.53) 5 (28) 1.92 (0.56–6.61) 64 (49–86) 0.051








27 (66) 1.42 (0.65–3.39) 10 (24) 1.61 (0.60–4.32) 69 (41–97) 0.381















38.64) 70 (37–85) 0.199





2 (28) 2.00 (0.34–11.80) 70 (34–91) 0.845





8 (50) 6.50(1.90–22.25) 13 (81)
3.31 (0.85–
12.85)
7 (44) 3.89 (1.17–12.89) 64 (24–91) 0.395







(48) 4.61 (1.63–13.03) 73 (23–101) 0.835
The 28 serotypes/serogroups with low incidence are not included in the table and were in descending order: 9N (n=11), 22 (n=11), 12 (n=10), 11 (n=9), 6C (n=9), 17 (n=4), 38 (n=4), 33 (n=4), 20 (n=4), 15 (n=3), 9A
(n=3), 31 (n=3), 23A (n=3), 7 (n=3), 9 (n=3), 7A (n=2), 35 (n=2), 18 (n=2), 13 (n=2), 10 (n=2), 8F (n=1), 5 (n=1), 28 (n=1), 27 (n=1), 23B (n=1), 23 (n=1), 19 (n=1), and, finally, 18F (n=1). Ten isolates were nontypable (1.9%)



















1. Serotypes were divided into three different classes de-
pending on their invasive potential in children according
to a meta-analysis by Brueggeman et al. [3], where car-
riage rates of serogroups and serotypes were compared
with their rates of IPD. Brueggeman and collaborators se-
lected serotype 14 as a reference since it is a single sero-
type with no subtypes, is among the most prevalent
invasive and carriage serotypes, and, finally, shows no evi-
dence of heterogeneity. Moreover, Brueggeman et al. de-
termined odds ratio (OR) with 95% confidence interval
(CI) compared to serotype 14. Pneumococcal serogroups
were divided into having a high, intermediate or low inva-
sive potential based upon this analysis. An OR >1 was as-
sociated with serogroups included in the highly invasive
serogroups [1,5,7]. Odds ratio 0.5-1 included the inter-
mediate invasive serogroups [4,9,14,18], and OR <0.5 com-
prised the low invasive serogroups (3, 6, 8, 15, 19, 23 and
33). Generalized Fisher’s exact test was used to compare
binary data between the three groups and Kruskal Wallis
test for ordinal data.
2. Serotypes were compared one by one to serotype 14
as a reference based upon the rationale described above.
Fisher’s test was included to compare binary data and
Mann-Whitney’s test was used for ordinal data. Odds ra-
tios, 95% CI and p-values were consequently calculated.
Ethical approval
This study was approved by The Regional Ethical Review
Board in Lund, Lund University, Sweden (2011/65). Indi-
vidual informed consent was not recommended by the
Ethical Board. The study was retrospective and all personal
data has been handled under strict secrecy and the results
in our study cannot be connected to individual patients.
Results
Invasive pneumococcal disease in south Sweden is
dominated by serotypes 3, 4, 7F, 9V and 14
In total, 513 patients were included in the analysis which
consisted of 246 men and 267 women. Median age was
67 years (range 19–101 years). The majority of patients
(87%) were diagnosed with pneumonia, 5% with menin-
gitis, 8% percent with unknown infection focus, and 3%
had two infection foci. Otitis, arthritis, osteitis, endocar-
ditis and epiglottitis were rare diagnoses.
We further analysed all pneumococcal strains, and the
distribution is presented in Table 1. In our collection
were 10 isolates non-typable. Serotypes 7F and 14 were
the most abundant representing 12.7% and 11.7% of the
isolates, respectively. The five most common serotypes
consisted of 50% of all isolates and the 12 most common
serotypes comprised 76% of all isolates. Antimicrobial
resistance was as expected very low, and only 2.5% of
patients were infected with PNSP. The MIC-values for
PcG was 2 mg/L in one, 1 mg/L in four and 0.125-0.5
mg/L in 8 of the pneumococcal isolates.
β-lactam antibiotics were included in the empirical
treatment of 488 patients, and 113 patients were treated
with two different classes of antibacterial agents. Accor-
ding to the Swedish guidelines, penicillin is the recom-
mended empirical treatment against pneumonia, and
was consequently given to 218 patients. Patients not
administered β-lactam antibiotics were treated with
clindamycin (n=12), erythromycin (n=5), doxycycline
(n=3), gentamicin (n=2), or vancomycin (n=2). One pa-
tient was not at all treated with antibacterial agents.
Pneumococcal serotype 3 causes more often septic shock
compared to serotype 14
The 28-day crude mortality rate for all patients was
12.3%, and after one year 19.5% of the patients were
dead. One patient infected with a PNSP having MIC
0.125 mg/L for PcG did not survive. A difference, albeit
not significant, was revealed between 28-day mortality
rate in serotype/ serogroups when divided into high
(7%), intermediate (13%) and low (14%) invasive poten-
tial (Table 2). Serotype 3 was the only serotype with a
significantly higher mortality (30%) when compared to
the reference serotype 14 (13%) (Table 1). Among the 12
















Highb (n = 85) 7 (8%) 6 (7%) 12 (14%) 41 (48%) 19 (22%) 62 (19–95)
Intermediatec
(n = 192) 18 (9%) 25 (13%) 29 (15%) 117 (61%) 52 (27%) 68 (20–97)
Lowd (n = 169) 17 (10%) 24 (14%) 24 (14%) 133 (79%) 74 (44%) 72 (23–101)
p-valuee p=0.911 p=0.293 p=0.984 p<0.001 p<0.001 p<0.001
ªSerogroups divided into groups depending of invasive potential according to Brueggeman et al. [3]. Sixty-seven IPD cases were excluded since the serotype was
not included in this classification.
bHigh invasive disease potential includes serotypes in serogroups 1, 5, and 7.
cIntermediate invasive disease potential includes serotypes in serogroups 4, 9, 14 and 18.
dLow invasive disease potential includes serotypes in serogroups 3, 6, 8, 15, 19, 23, and 33.
eUnivariate p-value for differences among the groups (high, intermediate and low invasive potential).
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most common serotypes, no cases of mortality were
noted amongst patients infected with serotype 23F, 1 or
19A. The mortality rate after 28 days, the incidence of
septic shock and furthermore ICU care for the most
common co-morbidities are presented in Table 3.
Fifteen% of the patients (n=79) were treated at ICU
and 33% of these individuals (n=26) died within 28 days.
We did not see any significant difference in sepsis sever-
ity and admission to ICU between the groups divided
according to invasive potential (Table 2). There was,
however, a significant difference (p=0.015) of IPD inci-
dence with unknown infection focus between the three
groups of pneumococcal serotypes with different inva-
sive potential. Infections with unknown foci were noted
in 11.2% of cases in the group with low invasive capacity
compared to 4.2% and 3.5% in the groups with inter-
mediate and high invasive potential, respectively. Sero-
type 3 caused significantly more often septic shock (OR
6.33 [CI 1.59-25.29]) compared to serotype 14. Despite
significance levels were not reached, septic shock was
more often seen when patients were infected with sero-
type 19F (OR 4.38 (0.79-24.24). Furthermore, serotypes
4, 7F, 8, 9V and 18C also had an OR >2 (Table 1).
Patients with IPD due to serotype 19F required signifi-
cantly more often intensive care (OR 6.50 [CI 1.90-
22.25]) than serotype 14. In summary, serotypes were
related to incidence of septic shock and clinical out-
come. Serotype 3 stood out as the most virulent sero-
type, and was closely followed by serotype 19F.
Patients infected with serotypes related to a high invasive
potential are younger and have fewer co-morbidities
Co-morbidities were found in 66% of the patients and
cardiovascular and lung diseases dominated and were
found in 27 and 24% of the individuals, respectively.
Patients infected with highly invasive serotypes were
younger, that is, median age was 62 years (range 19–95
years), and had a relatively low prevalence of co-
morbidities (48%). The median age in the group with
intermediate invasive potential was 68 years (range
20–97 years) and 61% were diagnosed with co-
morbidities. The median age was 72 years (range 23–101
years) in the group with low invasive serotypes and 79%
were diagnosed with co-morbidities. The differences be-
tween the groups were significant for age, co-morbidity,
or two or more co-morbidities (Table 2).
Patients infected with pneumococcal serotypes 3, 6A,
6B, 18C, 19F and 23 F had significantly more co-
morbidities per individual compared to patients infected
with serotype 14. Patients presenting with serotypes 1
and 7F were significantly younger than individuals suf-
fering from IPD with serotype 14 (Table 1). In conclu-
sion, we found that highly invasive serotypes [1,5,7]
caused IPD in younger and previously healthier individ-
uals, whereas low invasive serotypes (3, 6, 8, 15, 19, 23
and 33) caused IPD merely in the elderly with more
co-morbidities.
Discussion
The virulence of different pneumococcal serotypes most
probably differs significantly. Case fatality rate (CFR) is
usually studied as a clinical outcome, but is biased since
pneumococci with serotypes related to a low CFR infect
relatively healthier and younger individuals and vice
versa. Our hypothesis was that septic shock as a primary
clinical outcome would give a more valid picture of the
virulence since shock is a result of the immune response
induced by the virulent microorganism in question.
Due to the retrospective nature of this study incom-
plete data sets were occasionally found in the medical
records of patients with less severe disease. This may
underestimate the level of severe sepsis but not likely
the studied endpoint diagnosis septic shock. The groups
of serotypes with high, intermediate and low invasive po-
tential according to Brueggeman et al. are based on the
relation of carriage and IPD in children [3]. Whether
Table 3 Prevalence of co-morbidities, associated mortality, incidence of septic shock, and ICU admission per co-
morbidity
Type of co-morbiditya Number of patients (%) 28 day mortality (%) Septic shock (%) Admitted to the ICU (%)
Cardiovascular disease 136 (27%) 25 (18%) 18 (13%) 26 (19%)
Lung disease 125 (24%) 20 (16%) 20 (16%) 26 (21%)
Neurological disease 67 (13%) 12 (18%) 9 (13%) 10 (15%)
Diabetes mellitus 61 (12%) 10 (6%) 12 (20%) 12 (20%)
Solid cancer 50 (10%) 7 (14%) 5 (10%) 5 (10%)
Hematologic diseaseb 48 (10%) 9 (19%) 4 (8%) 5 (10%)
Immunosuppressionc 55 (11%) 11 (20%) 8 (14%) 11 (20%)
aOther reported co-morbidities were in descending order; renal disease (n=23), autoimmune disease (n=19), liver disease (n=17), splenectomy (n=4)
and HIV (n=3).
bHematologic disease includes hematological malignancies.
cPharmacological immunosuppression was noted if the patient was treated with biological drugs, methotrexate or corticosteroids equivalent
to ≥ 10 mg prednisolone.
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this is true also for adults have not been fully confirmed,
but the classification has, however, been used in studies
on adults [4,5]. In the present study, the number of iso-
lates for each serotype was relatively low, i.e., 23 sero-
types represented 10.1% of the isolates. Statistical
evaluation of serotypes with lower frequency was often
not possible and a lack of significance for many of the
serotypes may fall within a statistical type II error. Clus-
tering of serotypes was thus necessary. Serotype 14 was
chosen as a reference since it was a common serotype,
and has also been proven to be temporally and geo-
graphically stable [3].
We found that patients infected with high invasive
serotype pneumococci were significantly younger with
fewer co-morbidities. In contrast, patients infected with
low invasive potential serotypes were significantly older
and had more co-morbidities. Patients infected with high
invasive serotypes had lower 28-day mortality, albeit not
significant. Our results thus support the theory that
pneumococci related to serotypes with intermediate and
low invasive potential act as opportunistic bacteria, pri-
marily causing IPD in patient’s immunosupressed by
disease or high age, whereas high invasive serogroups
primarily act as primary pathogens and more frequently
affect younger and healthier individuals [5,11]. In line
with the findings of Jansen et al., we also found that pa-
tients infected with serotypes with low invasive potential
more often presented with unknown foci as a marker for
more severe disease [4].
The distribution of serogroups differs from other stud-
ies, also earlier Swedish studies done in the metropolitan
areas of Gothenburg and Stockholm [5,7]. These find-
ings reflect the tendency of serogroups to vary geograph-
ically and over time [22] that emphasizes the importance
of local surveillance. This issue is even more important
after the introduction of pneumococcal conjugate vac-
cines since replacement and a shift in circulating sero-
types may be expected.
Serotypes differ in their capacity to cause severe dis-
ease and IPD in various types of patients. In analogy
with Garcia-Vidal et al. [12], we found that serotype 3
gave significantly more often septic shock and higher
mortality compared to serotype 14. Serotype 3 stands
out amongst most other pneumococcal serotypes since
it has a large and mucoid polysaccharide capsule [11]
inhibiting phagocytosis [23]. Moreover, it is particularly
interesting since a hyporesponsiveness to serotype 3
after a PCV booster dose has been observed as well as a
lack of protection against clinical infection after vaccin-
ation [24]. In a recent study, Dagan et al. did not show
any decrease in nasopharyngeal carriage of serotype 3
after vaccination with PCV13 [25]. To our knowledge,
no clinical data is available supporting that PCV13,
where serotype 3 is included, would be protective against
this particular serotype. Serotype 3 pneumococci are
common colonizers and constituted five percent of the
1,128 pneumococcal nasopharyngeal disease carriage
strains in Skåne 2008 (Ahl et al., unpublished data).
Pneumococci with serotype 19F caused more often
septic shock than serotype 14, albeit not significantly,
but was associated with a significantly higher percentage
of patients that were admitted to the ICU (OR 6.50 [CI
1.90-22.25]) compared to serotype 14. This is in accord-
ance with the knowledge that serotype 19F is one of the
most encapsulated serotypes and is associated with a
high risk of mortality [11].
We found no significant difference in frequency of
septic shock and mortality between patients infected
with pneumococci having serotypes with high, inter-
mediate or low invasive potential. Since clinical sepsis is
a response to infection by the host immune system, an
explanation would be that patients infected with low in-
vasive serotypes more often are immunosenescent and
therefore do not clinically present severe disease. The
classification of serotypes according to their invasive po-
tential seems suboptimal for comparison of capacity to
cause septic shock since serotypes 3 and 6A/6B are both
classified as low invasive serotypes by Brueggeman et al.,
and thus caused more and less septic shock, respectively,
compared to serotype 14.
Future research to improve the vaccine protection
for serotype 3 is probably needed and special con-
cerns with serotype 3 have to be considered in fur-
ther studies of vaccination types and policies. Larger
prospective clinical and laboratory studies are re-
quired to study serotypes one by one, and to deter-
mine whether some serotypes are more virulent and
cause more severe clinical disease than others. Clin-
ical studies and/ or meta-analysis have to be large
enough to be able to compensate for confounding
factors such as age and co-morbidities, and to include
enough numbers of uncommon serotypes. Replace-
ment with non-vaccine pneumococcal serotypes as a
consequence of vaccination is a fact [26], and there-
fore it is important to study all aspects of emerging
serotypes.
Conclusions
Patients infected with S. pneumoniae serotype 3 signifi-
cantly more often suffered from septic shock compared
to patients with serotype 14. Our results support the
hypothesis that serotypes with high invasiveness mainly
cause IPD in younger patients with less co-morbidities.
In contrast, serotypes with low and intermediate invasive
potential mostly cause IPD in the elderly with defined
co-morbidities, and thus can be considered as oppor-
tunistic.
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